Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

Article Cardiac & Cardiovascular Systems

Worsening renal function in acute heart failure in the context of diuretic response

Johanna E. Emmens et al.

Summary: In two large cohorts of patients with acute heart failure (AHF), the occurrence of worsening renal function (WRF) in the first 4 days was not associated with worse outcomes when patients had a good diuretic response. The interaction between diuretic response and WRF should be considered in the management of AHF patients.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

Jasper Tromp et al.

Summary: The EMPULSE trial aims to assess the clinical benefits and safety of the SGLT2 inhibitor empagliflozin compared to placebo in patients hospitalized for AHF. Approximately 500 patients across North America, Europe, and Asia will be randomized to receive either empagliflozin or placebo, with the primary outcome being clinical benefit at 90 days. Secondary outcomes include safety assessments and changes in symptom scores and natriuretic peptides.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems